Cannabis Reformers Split Between Optimism and Outrage After DEA 'Baby Step' on CBD

The Drug Enforcement Administration announced Wednesday it’s making research into the non-intoxicating cannabis compound cannabidiol (CBD) easier, but advocates for legal access to what appears an effective treatment for epilepsy say the change doesn’t go nearly far enough.

The policy tweak will allow researchers to modify or expand existing federally approved CBD studies without having to undergo a potentially time-consuming review by the DEA, which along with the Food and Drug Administration acts as a gatekeeper to cannabis research.

DEA spokeswoman Barbara Carreno says there currently are 330 active cannabis studies, with more than 70 looking at CBD, a handful of which are clinical studies that may benefit from the new policy.

“If [researchers] adjusted their protocol and the amount they needed, they needed to change their registration,” Carreno explains. DEA review of changes took on average seven weeks, she says, and “if something needs to be modified and that happens frequently and every...

Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.